What share of Eli Lilly's revenue comes from weight-loss drugs?

Weight-loss drugs generate nearly two-thirds of Eli Lilly's revenue.

Who are Eli Lilly's competitors in the weight-loss drug market?

Key competitors include Novo Nordisk with Ozempic and Wegovy.

Eli Lilly Weight-Loss Drugs Now Generate Two-Thirds of Revenue

Eli Lilly's weight-loss drugs now generate nearly two-thirds of the pharmaceutical giant's revenue, underscoring their critical role for investors.

July 13, 2026

2 min read

Source: Motley Fool

Key Numbers

revenue share

two-thirds

According to a report from Motley Fool, Eli Lilly's (NYSE: LLY) weight-loss drugs now account for nearly two-thirds of the pharmaceutical giant's revenue. This significant shift in revenue mix highlights the enormous success of drugs like Mounjaro for diabetes and Zepbound for weight loss.

Drug Details

Mounjaro (tirzepatide) was initially approved for type 2 diabetes, while Zepbound received approval for weight loss. Both drugs target GLP-1 and GIP receptors, helping regulate appetite and blood sugar.

Context

This milestone comes amid rapid growth in the weight-loss drug market, with competition from companies like Novo Nordisk (Ozempic and Wegovy). Eli Lilly is benefiting from strong demand and increasing production capacity.

What This Means for Investors

For investors, the heavy reliance on weight-loss drugs means the company's performance is now closely tied to the success of these products. Any regulatory developments or new competition could significantly impact revenue.

Frequently Asked Questions

Eli Lilly produces Mounjaro (for diabetes) and Zepbound (for weight loss), both targeting GLP-1 and GIP receptors.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.